Vemurafenib in Langerhans cell histiocytosis: report of a pediatric patient and review of the literature.

about

Vemurafenib in Langerhans cell histiocytosis: report of a pediatric patient and review of the literature.

Item

http://www.wikidata.org/entity/Q55042378

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Vemurafenib in Langerhans cell ...... and review of the literature.

@en

Vemurafenib in Langerhans cell ...... and review of the literature.

@nl

type

Item

label

Vemurafenib in Langerhans cell ...... and review of the literature.

@en

Vemurafenib in Langerhans cell ...... and review of the literature.

@nl

prefLabel

Vemurafenib in Langerhans cell ...... and review of the literature.

@en

Vemurafenib in Langerhans cell ...... and review of the literature.

@nl

P1476

Vemurafenib in Langerhans cell ...... and review of the literature.

@en

P2093

Anne Heisig

http://www.w3.org/2001/XMLSchema#string

Dirk Schwabe

http://www.w3.org/2001/XMLSchema#string

Hans-Michael Kvasnicka

http://www.w3.org/2001/XMLSchema#string

Jan Sörensen

http://www.w3.org/2001/XMLSchema#string

Raphaela Schwentner

http://www.w3.org/2001/XMLSchema#string

Stefan Schöning

http://www.w3.org/2001/XMLSchema#string

Stefanie-Yvonne Zimmermann

http://www.w3.org/2001/XMLSchema#string

Thomas Lehrnbecher

http://www.w3.org/2001/XMLSchema#string

P2860

Recurrent BRAF mutations in Langerhans cell histiocytosis

Potential clinical implications of BRAF mutations in histiocytic proliferations.

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.

BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.

Detection and management of minimal residual disease in acute lymphoblastic leukemia.

Langerhans cell histiocytosis is a neoplasm and consequently its recurrence is a relapse: In memory of Bob Arceci.

Circulating cell-free BRAFV600E as a biomarker in children with Langerhans cell histiocytosis.

Langerhans cell histiocytosis research. Past, present, and future.

Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.

P304

22236-22240

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.18632/ONCOTARGET.25277

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Caroline Hutter

P577

2018-04-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29774135

http://www.w3.org/2001/XMLSchema#string

P932

5955145

http://www.w3.org/2001/XMLSchema#string